Skip to main content

Immaculada Raurell Saborit

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Immaculada Raurell Saborit

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

NANOPARTICULAS BIODEGRADABLES DE SIMVASTATINA COMO NUEVA HERRAMIENTA TERAPÉUTICA PARA LA ENFERMEDAD HEPÁTICA CRÓNICA

IP: Maria Nieves Martell Pérez-Alcalde
Collaborators: Immaculada Raurell Saborit, Ester Palacio Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI17/00754
Duration: 01/01/2018 - 31/12/2020

Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Macarena Simon-Talero Horga, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 130075
Reference: PI15/00066
Duration: 01/01/2016 - 31/10/2019

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Mecanismos de neuromodulación en la hipertensión portal: nuevas posibilidades terapéuticas en la cirrosis hepática

IP: Maria Nieves Martell Pérez-Alcalde
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 69575
Reference: PI13/01289
Duration: 01/01/2014 - 30/06/2017

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Edoardo Caronna

Edoardo Caronna

Postdoctoral researcher
Headache and Neurological Pain
Read more
Selen Ozkan

Selen Ozkan

Predoctoral researcher
Clinical and Translational Bioinformatics
Read more
Maria Victoria Gonzalez Martinez

Maria Victoria Gonzalez Martinez

Senior researcher
Pediatric Neurology
Read more
Tamara Garcia Antolinez

Tamara Garcia Antolinez

Zelador/a
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.